• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经静脉与皮下植入式心律转复除颤器治疗效果的比较评估:一项更新的系统评价和荟萃分析

Comparative Assessment of Transvenous versus Subcutaneous Implantable Cardioverter-defibrillator Therapy Outcomes: An Updated Systematic Review and Meta-analysis.

作者信息

Nso Nso, Nassar Mahmoud, Lakhdar Sofia, Enoru Sostanie, Guzman Laura, Rizzo Vincent, Munira Most S, Radparvar Farshid, Thambidorai Senthil

机构信息

Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, NY, USA.

Department of Medicine, Icahn School of Medicine at Mount Sinai/NYC H+H/Queens, NY, USA.

出版信息

Int J Cardiol. 2022 Feb 15;349:62-78. doi: 10.1016/j.ijcard.2021.11.029. Epub 2021 Nov 19.

DOI:10.1016/j.ijcard.2021.11.029
PMID:34801615
Abstract

BACKGROUND

Subcutaneous (S-ICD) and transvenous (TV-ICD) implantable cardioverter-defibrillator devices effectively reduce the incidence of sudden cardiac death in patients at a high risk of ventricular arrhythmias. This study aimed to evaluate the safe replacement of TV-ICD with S-ICD based on updated recent evidence.

METHODS

We systematically searched EMBASE, JSTOR, PubMed/MEDLINE, and Cochrane Library on 30 July 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

RESULTS

We identified 26 studies that examined 7542 (58.27%) patients with S-ICD and 5400 (41.72%) with TV-ICD. The findings indicated that, compared to patients with TV-ICD, patients with S-ICD had a lower incidence of defibrillation lead failure (odds ratio [OR], 0.12; 95% confidence interval [CI], 0.01-0.98; p = 0.05), lead displacement or fracture (OR, 0.25; 95% CI, 0.12-0.86; p = 0.0003), pneumothorax and/or hemothorax (OR: 0.22, 95% CI 0.05, 0.97, p = 0.05), device failure (OR: 0.70, 95% CI 0.51, 0.95, p = 0.02), all-cause mortality (OR: 0.44 [95% CI 0.32, 0.60], p < 0.001), and lead erosion (OR: 0.01, 95% CI 0.00, 0.05, p < 0.001). Patients with TV-ICD had a higher incidence of pocket complications than patients with S-ICD (OR, 2.13; 95% CI, 1.23-3.69; p = 0.007) and a higher but insignificant incidence of inappropriate sensing (OR, 3.53; 95% CI, 0.97-12.86; p = 0.06).

CONCLUSIONS

The S-ICD algorithm was safer and more effective than the TV-ICD system as it minimized the incidence of pocket complications, lead displacement or fracture, inappropriate sensing, defibrillation lead failure, pneumothorax/hemothorax, device failure, lead erosion, and all-cause mortality. Future studies should explore the scope of integrating novel algorithms with the current S-ICD systems to improve cardiovascular outcomes.

摘要

背景

皮下植入式心律转复除颤器(S-ICD)和经静脉植入式心律转复除颤器(TV-ICD)可有效降低室性心律失常高危患者的心源性猝死发生率。本研究旨在基于最新证据评估用S-ICD安全替代TV-ICD。

方法

我们于2021年7月30日按照系统评价和Meta分析的首选报告项目(PRISMA)指南,系统检索了EMBASE、JSTOR、PubMed/MEDLINE和Cochrane图书馆。

结果

我们纳入了26项研究,共涉及7542例(58.27%)使用S-ICD的患者和5400例(41.72%)使用TV-ICD的患者。研究结果表明,与TV-ICD患者相比,S-ICD患者的除颤导线故障发生率更低(优势比[OR]为0.12;95%置信区间[CI]为0.01 - 0.98;p = 0.05)、导线移位或断裂发生率更低(OR为0.25;95% CI为0.12 - 0.86;p = 0.0003)、气胸和/或血胸发生率更低(OR为0.22,95% CI为0.05,0.97,p = 0.05)、设备故障发生率更低(OR为0.70,95% CI为0.51,0.95,p = 0.02)、全因死亡率更低(OR为0.44 [95% CI为0.32,0.60],p < 0.001)以及导线侵蚀发生率更低(OR为0.01,95% CI为0.00,0.05,p < 0.001)。TV-ICD患者的囊袋并发症发生率高于S-ICD患者(OR为2.13;95% CI为1.23 - 3.69;p = 0.007),不适当感知发生率虽更高但无统计学意义(OR为3.53;95% CI为0.97 - 12.86;p = 0.06)。

结论

S-ICD算法比TV-ICD系统更安全、更有效,因为它将囊袋并发症、导线移位或断裂、不适当感知、除颤导线故障、气胸/血胸、设备故障、导线侵蚀和全因死亡率的发生率降至最低。未来研究应探索将新算法与当前S-ICD系统整合的范围,以改善心血管结局。

相似文献

1
Comparative Assessment of Transvenous versus Subcutaneous Implantable Cardioverter-defibrillator Therapy Outcomes: An Updated Systematic Review and Meta-analysis.经静脉与皮下植入式心律转复除颤器治疗效果的比较评估:一项更新的系统评价和荟萃分析
Int J Cardiol. 2022 Feb 15;349:62-78. doi: 10.1016/j.ijcard.2021.11.029. Epub 2021 Nov 19.
2
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.皮下与经静脉植入式心脏除颤器治疗:病例对照研究的荟萃分析。
JACC Clin Electrophysiol. 2017 Dec 26;3(13):1475-1483. doi: 10.1016/j.jacep.2017.07.017. Epub 2017 Sep 27.
3
Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis.皮下与经静脉植入式除颤器:一项更新的荟萃分析。
Heart Rhythm. 2021 Mar;18(3):382-391. doi: 10.1016/j.hrthm.2020.11.013. Epub 2020 Nov 16.
4
Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.皮下与经静脉植入式除颤器治疗的长期临床结果。
J Am Coll Cardiol. 2016 Nov 8;68(19):2047-2055. doi: 10.1016/j.jacc.2016.08.044.
5
Subcutaneous versus transvenous implantable cardioverter defibrillators in children and young adults: A meta-analysis.皮下与经静脉植入式心律转复除颤器在儿童和青少年中的比较:一项荟萃分析。
Pacing Clin Electrophysiol. 2022 Dec;45(12):1409-1414. doi: 10.1111/pace.14603. Epub 2022 Oct 27.
6
Shock Without Wires: A Look at Subcutaneous Implantable Cardioverter-Defibrillator Compared to Transvenous Implantable Cardioverter-Defibrillator for Ventricular Arrhythmias.无导线除颤器:皮下植入式除颤器与经静脉植入式除颤器治疗室性心律失常的比较。
Curr Probl Cardiol. 2022 Sep;47(9):100927. doi: 10.1016/j.cpcardiol.2021.100927. Epub 2021 Jul 3.
7
Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.SIMPLE 和 EFFORTLESS 研究中皮下植入式和经静脉植入式心脏复律除颤器治疗的倾向评分匹配比较。
Europace. 2018 Sep 1;20(FI2):f240-f248. doi: 10.1093/europace/euy083.
8
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity Score-Matched Studies.皮下与经静脉植入式心脏除颤器治疗的比较:随机试验和倾向评分匹配研究的系统评价和荟萃分析。
J Am Heart Assoc. 2022 Jun 7;11(11):e024756. doi: 10.1161/JAHA.121.024756. Epub 2022 Jun 3.
9
The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator.需要在植入皮下植入式心律转复除颤器的患者中使用后续的经静脉系统。
Heart Rhythm. 2022 Dec;19(12):1958-1964. doi: 10.1016/j.hrthm.2022.06.030. Epub 2022 Jun 30.
10
Subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis.皮下植入式心律转复除颤器在心脏性猝死一级和二级预防中的应用:一项荟萃分析。
Pacing Clin Electrophysiol. 2019 Sep;42(9):1253-1268. doi: 10.1111/pace.13774. Epub 2019 Aug 22.

引用本文的文献

1
Current state of heart failure treatment: are mesenchymal stem cells and their exosomes a future therapy?心力衰竭治疗的现状:间充质干细胞及其外泌体是未来的治疗方法吗?
Front Cardiovasc Med. 2025 Apr 28;12:1518036. doi: 10.3389/fcvm.2025.1518036. eCollection 2025.
2
Design of a post-market registry for the extravascular implantable cardioverter-defibrillator: The Enlighten Study.血管外植入式心脏复律除颤器上市后注册研究的设计:启迪研究。
Heart Rhythm O2. 2024 Oct 16;6(1):64-69. doi: 10.1016/j.hroo.2024.09.022. eCollection 2025 Jan.
3
Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study.
经长期随访的血管外植入式心脏复律除颤器的性能与安全性:关键研究的最终结果
Circulation. 2025 Jan 28;151(4):322-332. doi: 10.1161/CIRCULATIONAHA.124.071795. Epub 2024 Sep 26.
4
S-ICD Implantation "Tips and Tricks".皮下植入式心律转复除颤器(S-ICD)植入术“技巧与窍门”
Rev Cardiovasc Med. 2023 Jul 10;24(7):195. doi: 10.31083/j.rcm2407195. eCollection 2023 Jul.
5
Double-device therapy in a patient with long QT syndrome.长QT综合征患者的双装置治疗
J Arrhythm. 2024 Mar 19;40(3):639-642. doi: 10.1002/joa3.13027. eCollection 2024 Jun.
6
Deep learning-based prediction of major arrhythmic events in dilated cardiomyopathy: A proof of concept study.基于深度学习的扩张型心肌病主要心律失常事件预测:概念验证研究。
PLoS One. 2024 Feb 29;19(2):e0297793. doi: 10.1371/journal.pone.0297793. eCollection 2024.
7
Comparison of Preoperative ECG Screening and Device-Based Vector Analysis in Patients Receiving a Subcutaneous Implantable Cardioverter-Defibrillator.比较接受皮下植入式心脏除颤器患者的术前心电图筛查和基于设备的向量分析。
Medicina (Kaunas). 2023 Dec 16;59(12):2186. doi: 10.3390/medicina59122186.
8
Real-world evidence for the use of subcutaneous implantable cardioverter-defibrillators in China: A single-center experience.中国皮下植入式心律转复除颤器应用的真实世界证据:单中心经验。
Herz. 2023 Dec;48(6):462-469. doi: 10.1007/s00059-023-05192-4. Epub 2023 Aug 4.
9
Hyperkalemia Causing Inappropriate Subcutaneous Implantable Cardioverter Defibrillator Shocks in a Patient with End-Stage Renal Disease: A Case Report and Literature Review.终末期肾病患者高钾血症导致皮下植入式心律转复除颤器不适当电击:病例报告及文献复习
Cureus. 2022 Nov 5;14(11):e31137. doi: 10.7759/cureus.31137. eCollection 2022 Nov.
10
Subcutaneous implantable cardioverter-defibrillator: a systematic review of comparative effectiveness and safety.皮下植入式心律转复除颤器:比较有效性和安全性的系统评价。
ESC Heart Fail. 2023 Apr;10(2):808-823. doi: 10.1002/ehf2.14249. Epub 2022 Nov 29.